Core Viewpoint - Green Leaf Pharmaceutical (02186) has seen a nearly 3% increase in stock price, attributed to the successful inclusion of five new products in the National Medical Insurance Catalog for 2025 and the Commercial Health Insurance Innovative Drug Catalog for 2025 [1]. Group 1: Stock Performance - Green Leaf Pharmaceutical's stock rose by 2.66%, reaching HKD 3.09, with a trading volume of HKD 8.3751 million [1]. Group 2: Product Inclusion - Five new products from Green Leaf Pharmaceutical have been successfully included in the National Medical Insurance Catalog and the Commercial Health Insurance Innovative Drug Catalog for 2025 [1]. - The new products include: - MiMeiXin® (Oxycodone Naloxone Extended-Release Tablets) and RuiBaiLai® (Paliperidone Palmitate Injection (II)) are newly included in the National Medical Insurance Catalog [1]. - ZanBiJia® (Injectable Lurbinectedin) has been successfully included in the Commercial Health Insurance Innovative Drug Catalog [1]. - BaiTuoWei® (Injectable Goserelin Microspheres) and RuiKeTuo® (Injectable Risperidone Microspheres (II)) have successfully renewed their inclusion in the National Medical Insurance Catalog [1].

Core Viewpoint - Green Leaf Pharmaceutical (02186) saw a nearly 3% increase in stock price, currently at HKD 3.09, with a trading volume of HKD 8.3751 million, following the announcement of five new products being included in the National Medical Insurance Catalog for 2025 and the Commercial Health Insurance Innovative Drug Catalog for 2025 [1] Group 1 - The five new products include: - Mimesin® (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai® (Paliperidone Palmitate Injection (II)) are newly included in the National Medical Insurance Drug Catalog [1] - Zanbija® (Injectable Lurbinectedin) has been successfully included in the Commercial Health Insurance Innovative Drug Catalog [1] - Baituowei® (Injectable Goserelin Microspheres) and Ruiketuo® (Injectable Risperidone Microspheres (II)) have successfully renewed their inclusion in the National Medical Insurance Drug Catalog [1]

Core Viewpoint - Green Leaf Pharmaceutical (02186) has successfully included five new products in the National Medical Insurance Drug List (2025) and the Commercial Health Insurance Innovative Drug List (2025) [1] Group 1: New Product Inclusion - The five new products include: - Mimesin® (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai® (Paliperidone Palmitate Injection (II)) are newly included in the National Medical Insurance Drug List [1] - Zanbija® (Injectable Lurbinectedin) has been successfully included in the Commercial Health Insurance Innovative Drug List [1] - Baituowei® (Injectable Goserelin Microspheres) and Ruiketuo® (Injectable Risperidone Microspheres (II)) have successfully renewed their inclusion in the National Medical Insurance Drug List [1]